Relay Therapeutics (RLAY) Cash from Investing Activities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash from Investing Activities data on file, last reported at $32.9 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 22.52% year-over-year to $32.9 million in Q1 2026; TTM through Mar 2026 was $183.2 million, a 2102.79% increase from a year earlier, with the FY2025 full-year figure at $192.8 million, up 569.29% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $32.9 million, down from $35.5 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for RLAY reached as high as $75.3 million in Q1 2023 and fell as low as -$146.9 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged $14.9 million across 5 years, with a median of $39.7 million in 2025.
• Across the five-year window, Cash from Investing Activities slumped 276.78% in 2024 and surged 303.24% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$146.9 million in 2022, then soared by 140.61% to $59.7 million in 2023, then plunged by 51.41% to $29.0 million in 2024, then gained by 22.29% to $35.5 million in 2025, then declined by 7.22% to $32.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $32.9 million in Q1 2026, $35.5 million in Q4 2025, and $39.7 million in Q3 2025.